News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
596,391 Results
Type
Article (42897)
Company Profile (318)
Press Release (553176)
Section
Business (167912)
Career Advice (2443)
Deals (30355)
Drug Delivery (107)
Drug Development (78761)
Employer Resources (148)
FDA (14402)
Job Trends (12996)
News (296327)
Policy (28537)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
Academia (2671)
Academic (1)
Accelerated approval (3)
Adcomms (26)
Allergies (79)
Alliances (42925)
ALS (89)
Alzheimer's disease (1412)
Antibody-drug conjugate (ADC) (126)
Approvals (14390)
Artificial intelligence (231)
Autoimmune disease (17)
Automation (14)
Bankruptcy (325)
Best Places to Work (10685)
BIOSECURE Act (15)
Biosimilars (91)
Biotechnology (258)
Bladder cancer (63)
Brain cancer (27)
Breast cancer (249)
Cancer (1980)
Cardiovascular disease (163)
Career advice (2050)
Career pathing (31)
CAR-T (147)
Cell therapy (409)
Cervical cancer (16)
Clinical research (63584)
Collaboration (754)
Compensation (328)
Complete response letters (24)
COVID-19 (2561)
CRISPR (41)
C-suite (218)
Cystic fibrosis (101)
Data (1890)
Decentralized trials (2)
Denatured (15)
Depression (46)
Diabetes (239)
Diagnostics (5799)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (111)
Drug pricing (101)
Drug shortages (23)
Duchenne muscular dystrophy (89)
Earnings (61456)
Editorial (35)
Employer branding (20)
Employer resources (135)
Events (89327)
Executive appointments (643)
FDA (15454)
Featured Employer (44)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (676)
Gene editing (102)
Generative AI (20)
Gene therapy (299)
GLP-1 (712)
Government (4228)
Grass and pollen (3)
Guidances (45)
Healthcare (17261)
Huntington's disease (24)
IgA nephropathy (25)
Immunology and inflammation (117)
Indications (27)
Infectious disease (2695)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (48)
Intellectual property (84)
Interviews (523)
IPO (14243)
IRA (45)
Job creations (2757)
Job search strategy (1683)
Kidney cancer (10)
Labor market (18)
Layoffs (443)
Leadership (19)
Legal (6064)
Liver cancer (71)
Lung cancer (297)
Lymphoma (124)
Machine learning (2)
Management (52)
Manufacturing (246)
MASH (66)
Medical device (11099)
Medtech (11103)
Mergers & acquisitions (16552)
Metabolic disorders (643)
Multiple sclerosis (69)
NASH (23)
Neurodegenerative disease (91)
Neuropsychiatric disorders (31)
Neuroscience (1912)
NextGen: Class of 2025 (5970)
Non-profit (4119)
Northern California (2191)
Now hiring (34)
Obesity (345)
Opinion (231)
Ovarian cancer (72)
Pain (79)
Pancreatic cancer (76)
Parkinson's disease (137)
Partnered (17)
Patents (198)
Patient recruitment (92)
Peanut (48)
People (54035)
Pharmaceutical (56)
Pharmacy benefit managers (13)
Phase I (19960)
Phase II (28090)
Phase III (20920)
Pipeline (973)
Podcasts (67)
Policy (110)
Postmarket research (2391)
Preclinical (8407)
Press Release (60)
Prostate cancer (91)
Psychedelics (37)
Radiopharmaceuticals (254)
Rare diseases (376)
Real estate (4497)
Recruiting (60)
Regulatory (20176)
Reports (25)
Research institute (2276)
Resumes & cover letters (359)
Rett syndrome (3)
RNA editing (2)
RSV (36)
Schizophrenia (69)
Series A (119)
Series B (79)
Service/supplier (3)
Sickle cell disease (52)
Southern California (1975)
Special edition (13)
Spinal muscular atrophy (153)
Sponsored (27)
Startups (3180)
State (2)
Stomach cancer (13)
Supply chain (54)
The Weekly (50)
United States (19333)
Vaccines (631)
Venture capitalists (36)
Webinars (11)
Weight loss (242)
Women's health (27)
Worklife (16)
Date
Today (18)
Last 7 days (547)
Last 30 days (2449)
Last 365 days (32082)
2025 (7308)
2024 (33635)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50008)
2019 (42544)
2018 (32073)
2017 (29661)
2016 (28191)
2015 (32973)
2014 (25388)
2013 (20574)
2012 (21779)
2011 (22687)
2010 (20427)
Location
Africa (742)
Alabama (51)
Alaska (4)
Arizona (164)
Arkansas (12)
Asia (36257)
Australia (7206)
California (5090)
Canada (1778)
China (447)
Colorado (228)
Connecticut (223)
Delaware (122)
Europe (81310)
Florida (747)
Georgia (170)
Idaho (55)
Illinois (447)
India (21)
Indiana (257)
Iowa (6)
Japan (137)
Kansas (91)
Kentucky (21)
Louisiana (8)
Maine (50)
Maryland (788)
Massachusetts (3799)
Michigan (194)
Minnesota (322)
Mississippi (2)
Missouri (72)
Montana (24)
Nebraska (22)
Nevada (49)
New Hampshire (65)
New Jersey (1468)
New Mexico (25)
New York (1462)
North Carolina (864)
North Dakota (5)
Northern California (2191)
Ohio (168)
Oklahoma (10)
Oregon (32)
Pennsylvania (1118)
Puerto Rico (9)
Rhode Island (24)
South America (1014)
South Carolina (16)
South Dakota (1)
Southern California (1975)
Tennessee (81)
Texas (739)
Utah (159)
Virginia (119)
Washington D.C. (52)
Washington State (474)
West Virginia (3)
Wisconsin (42)
596,391 Results for "calliditas therapeutics formerly known as pharmalink".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Calliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics AB today announced that its management will be attending the following upcoming investor and industry conferences.
April 9, 2024
·
1 min read
Deals
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas.
May 28, 2024
·
7 min read
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics AB today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO ® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN).
May 28, 2024
·
8 min read
Deals
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.
May 28, 2024
·
24 min read
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics AB today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26, 2024.
May 15, 2024
·
6 min read
Business
Calliditas Therapeutics’ 2023 Annual Report Published
Calliditas Therapeutics AB, announces that the Annual Report for 2023 now is available at the company’s website.
April 24, 2024
·
3 min read
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.
April 8, 2024
·
8 min read
Deals
Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics
The potential purchase by the Japanese conglomerate could secure access to Calliditas’ IgA nephropathy therapy Tarpeyo, which won the FDA’s full approval in December 2023.
May 28, 2024
·
2 min read
·
Tyler Patchen
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
1 of 59,640
Next
